Company intelligence / Profile preview

Sublimed

Moirans, Auvergne-Rhône-Alpes, Francesubli-med.com ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

Sublimed has developed actiTENS, a wearable, smartphone-controlled transcutaneous electrical nerve stimulation (TENS) device for chronic pain management. Clinical studies in knee osteoarthritis patients demonstrated that actiTENS is superior to weak opioids like tramadol or opium powder in reducing pain and improving quality of life. The product is CE-marked, FDA-cleared as of December 2020, reimbursed by French social security, and used by over 15,000 regular users since its market launch in France in 2018.

Therapeutic areas: Women's HealthNeurologyRheumatology
Modalities: DeviceNon-pharmacological therapy (Transcutaneous electrical nerve stimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

actiTENS

Commercial

Indications: Chronic pain

Beyond the preview

Go deeper on Sublimed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sublimed.

Explore the full profile